510(k) Report

510(k) · Cleared

Cleared

xTAG Gastrointestinal Pathogen Panel (GPP), xTAG Data Analysis Software (TDAS GPP)

K191160510(k) SpecialCleared Nov 4, 2019187-day reviewClass II21 CFR 866.3990

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Luminex Molecular Diagnostics, Inc. · PCH Gastrointestinal Pathogen Panel Multiplex Nucleic Acid-Based Assay System

Cleared on Nov 4, 2019 after a 187-day review. FDA’s file for it is a 510(k) statement, which names no predicate.

Decided
Nov 4, 2019
Review
187 days
Class
Class II
Product code
PCH
Recalls
None
Predicates
0

FDA’s file for it is a 510(k) statement, which names no predicate.

FIG. 1 — Lineage of K191160Source: FDA 510(k) database · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA 510(k) statement (indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in PCH? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new PCH device

  1. #1 K220062 QIAstat-Dx Gastrointestinal Panel 2score 16.7 · 2 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against?

FDA’s file for it is a 510(k) statement, which names no predicate.

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

How does its category compare?

All PCH devices

PCH Gastrointestinal Pathogen Panel Multiplex Nucleic Acid-Based Assay System: FDA decisions, review times, recalls and adverse event reports over 20 years. 2019, this device’s year, is highlighted.

FDA decisions per year · PCH

7in 2025

2013: 32014: 62015: 22016: 22017: 12018: 42019: 42022: 22023: 12024: 32025: 72026 (partial year): 3
2007high 7 (2025) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · PCH

89in 2025

2014: 120 days median2018: 105 days median2019: 191 days median2024: 271 days median2025: 89 days median2026 (partial year): 176 days median
2007high 271 (2024) · low 89 (2025)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · PCH

5in 2025

2023: 12025: 5
2007high 5 (2025) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · PCH

40in 2025

2014: 12019: 42021: 262022: 472023: 622024: 452025: 40
2007high 62 (2023) · low 0 (2007)2025

MAUDE reports naming product code PCH, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20133—00
2014612001
20152—00
20162—00
20171—00
2018410500
2019419104
20200—00
20210—026
20222—047
20231—162
20243271045
2025789540
202631760—

What is it indicated for?

The xTAG Gastrointestinal Pathogen Panel (GPP) is a multiplexed nucleic acid test intended for the simultaneous qualitative detection and identification of multiple viral, bacterial and parasitic nucleic acids in human stool specimens or human stool in Cary-Blair media from individuals with signs and symptoms of infectious colitis or gastroenteritis. The following pathogen types, subtypes, and toxin genes are identified using the xTAG GPP: Viruses…

Read the full statement (349 words)

The xTAG Gastrointestinal Pathogen Panel (GPP) is a multiplexed nucleic acid test intended for the simultaneous qualitative detection and identification of multiple viral, bacterial and parasitic nucleic acids in human stool specimens or human stool in Cary-Blair media from individuals with signs and symptoms of infectious colitis or gastroenteritis. The following pathogen types, subtypes, and toxin genes are identified using the xTAG GPP:

Viruses

*Adenovirus 40/41

*Norovirus GI/GII

*Rotavirus A

Bacteria

*Campylobacter (C. jejuni, C. coli, and C. lari only)

*Clostridium difficile (C. difficile) toxin A/B

*Escherichia coli (E. coli) O157

*Enterotoxigenic E. coli (ETEC) LT/ST

*Salmonella

*Shiga-like Toxin producing E. coli (STEC) stx 1/stx 2

Shigella (S. boydii, S. sonnei, S. flexneri, and S. dysenteriae)

*Vibrio cholerae (V. cholerae) cholera toxin gene (ctx)

Parasites

*Cryptosporidium (C. parvum and C. hominis only)

*Entamoeba histolytica (E. histolytica)

*Giardia (G. lamblia only, also known as G. intestinalis and G. duodenalis)

The detection and identification of specific gastrointestinal microbial nucleic acid from individuals exhibiting signs and symptoms of gastrointestinal infection aids in the diagnosis of gastrointestinal infection when used in conjunction with clinical evaluation, laboratory findings, and epidemiological information. A gastrointestinal microorganism multiplex nucleic acid-based assay also aids in the detection and identification of acute gastroenteritis in the context of outbreaks. xTAG GPP positive results are presumptive and must be confirmed by FDA-cleared tests or other acceptable reference methods.

The results of this test should not be used as the sole basis for diagnosis, treatment, or other patient management decisions. Confirmed positive results do not rule out co-infection with other organisms that are not detected by this test, and may not be the sole or definitive cause of patient illness. Negative XTAG GPP results in the setting of clinical illness compatible with gastroenteritis may be due to infection by pathogens that are not detected by this test or non-infectious causes such as ulcerative colitis, irritable bowel syndrome, or Crohn's disease.

xTAG GPP is not intended to monitor or guide treatment for C. difficile infections.

The xTAG GPP test is indicated for use with the Luminex 100/200™ and MAGPIX instruments with XPONENT software.

Indications for use read by OCR from a scanned FDA 510(k) statement, so letters may be misread. Check the PDF before quoting it.

Cite this page

510(k) Report. “K191160: xTAG Gastrointestinal Pathogen Panel (GPP), xTAG Data Analysis Software (TDAS GPP).” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K191160

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Page last updated Nov 3, 2026